Person who experienced the adverse event (patient)
Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
124897782 | 12489778 | 2 | F | 20160805 | 20160622 | 20160817 | PER | US-PFIZER INC-2016311558 | PFIZER | 6.00 | YR | F | Y | 0.00000 | 20160817 | MD | US | US |
Drug(s) used by person
Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
124897782 | 12489778 | 1 | PS | CYTARABINE. | CYTARABINE | 1 | Intravenous (not otherwise specified) | 1000 MG/M2, 2X/DAY (Q12H) X 4D | 71868 | 1000 | MG/M**2 | BID | |||||||
124897782 | 12489778 | 2 | SS | MITOXANTRONE HCL | MITOXANTRONE HYDROCHLORIDE | 1 | UNK | U | 76871 |
Indications of drugs used
Event ID | CASEID | INDI DRUG SEQ | INDI PT |
---|---|---|---|
124897782 | 12489778 | 1 | Acute myeloid leukaemia |
124897782 | 12489778 | 2 | Acute myeloid leukaemia |
Outcome of event
no results found |
Reactions reported
Event ID | CASEID | DRUG REC ACT | PT |
---|---|---|---|
124897782 | 12489778 | Acute myeloid leukaemia | |
124897782 | 12489778 | Disease progression |
Reporting Sources (this data is often not reported and may therefore be missing here)
no results found |
Therapies reported
Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
---|---|---|---|---|---|---|
124897782 | 12489778 | 1 | 201205 | 201605 | 0 |